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Summary
Objectives: To describe the clinical and microbiological features of Dientamoeba fragilis and
Giardia lamblia infected patients, and to analyze the genetic variation of D. fragilis strains.
Methods: For a period of two years, all stool samples collected from patients suspected of having
a parasitic gastrointestinal infection were examined according to our specific triple feces test
(TFT) protocol. A retrospective case-control study was performed on D. fragilis and G. lamblia
infected patients. Furthermore, PCR and genotyping by restriction fragment length polymorph-
ism (RFLP) were performed upon the former.
Results: D. fragilis (6.3%) and G. lamblia (7.1%) were the most common pathogenic protozoa
isolated out of 448 patients studied. Symptomsmost frequently encounteredwith D. fragilis and
G. lamblia infection were abdominal pain (69.2% and 72.4%, respectively) and diarrhea (61.5%
and 79.3%, respectively). However, patients with D. fragilis infections suffered significantly less
frequently from nausea and/or vomiting, anorexia and weight loss. After treatment, all D.
fragilis and G. lamblia infected patients presenting a negative TFT follow-up also reported a§ Presented in part at the 11th International Congress on Infectious Diseases, Cancun, Mexico, 4—8 March 2004 (Abstract P63.020).
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Dientamoeba fragilis is a protozoan found in the gastroin-
testinal tract of humans. Originally D. fragiliswas considered
to be an amoeba with no identified cyst stage, but based on
phylogenetic data, ultrastructural characteristics and anti-
genic similarity to Trichomonas and Histomonas, it has now
been classified as a flagellate.1,2 It was considered a harmless
commensal organism with a worldwide prevalence varying
between 0.5% and 42%.3 However more recent literature
indicates that D. fragilis could be a potential enteric patho-
gen with symptomatology observed in 20—58% of infected
cases.4 Symptomatology includes a large range of gastroin-
testinal symptoms, including diarrhea, loose stools, abdom-
inal pain and abdominal cramps.3—6
As not all infected persons experience symptoms, various
authors have developed the hypothesis that D. fragilis could
be a heterogeneous species with non-pathogenic and patho-
genic variants with similar morphology but with different
pathogenicity.3,7 In a first report on the variability in D.
fragilis, Johnson and Clark analyzed the 16S-like ribosomal
subunit DNA sequence of 12 human isolates obtained from
culture by restriction fragment length polymorphism (RFLP)
and found the existence of two genetically distinct types of
D. fragilis.8 In a later set of samples, they were able to find
only one genotype.3 Recently, Peek et al. described a PCR
procedure for the effective isolation of D. fragilis from non-
preserved stool specimens, without the need for prior
culturing of the organism.9 In this study only genotype 1
was observed suggesting that genotype 2 is either very rare
or that the culture procedure facilitates detection of the
more rare genotype 2. Because samples analyzed were only
from Dutch patients it remains unclear whether D. fragilis
from other countries would also display such a restricted
genetic variation.
The aim of this study was to compare the prevalence
and clinical features of D. fragilis and Giardia lamblia in
patients suspected of suffering from a parasitic gastroin-
testinal illness. Furthermore genotypic analysis of D. fragilis
strains was performed to confirm the existence of two
distinct genotypes.
Methods
This study took place at the Saint-Pierre University Hospital
located in the central area of Brussels. From January 2002
to December 2003, 1207 stool samples were obtained from
448 outpatients who were clinically suspected to have a
gastrointestinal infection caused by parasites. These were
examined according to the protocol of our triple feces
test (TFT).10In the absence of international guidelines for parasite
stool examination, physicians follow Cumitech 30A’s recom-
mendations and systematically order parasite examination
in cases of: eosinophilia, chronic diarrhea, abdominal dis-
comfort, especially following recent travel in a foreign
country, and acute diarrhea after exclusion of common
causes of diarrhea.11 The TFTset is a collection kit containing
one empty tube and two tubes filled with sodium acetate
acetic acid formalin (SAF) preservative; these have to be
filled with stool samples on three consecutive days: at day 1
in a tube with SAF, at day 2 in an empty tube and at day 3 in
a tube with SAF.
SAF fixed stool specimens were examined for vegetative
stages of protozoa using direct wet preparation. From the
unpreserved stool specimen (TFT2, collected at day 2) sedi-
ment obtained with the routine ethylacetate-sedimentation
technique, was studied with a direct wet smear for protozoan
cysts and helminth eggs and auramine staining for Cryptos-
poridium. For direct wet mounts, an area equivalent to a
coverslip of 22  22 mm was examined by bright-field micro-
scopy at100 and400 magnifications. From TFT1 and TFT3
(stool from first and third collection day) direct smears were
studied with Kop-Color for vegetative and cyst stages of
protozoa. When parasites were observed but identification
could not be made on the wet smear, a permanent staining
was performed with chlorazol black.10 Next, 200 oil-immer-
sion fields using bright-field microscopy at 600 magnifica-
tion were examined.
All unpreserved stool samples were also examined
macroscopically for gross blood and mucus and routinely
cultured for common bacterial pathogens using conven-
tional culture media (xylose—lysine—deoxycholate (XLD)
agar, Salmonella—Shigella (SS) agar, Hektoen enteric (HE)
agar, and cefsulodin—irgasan—novobiocin (CIN) agar). A
specific culture protocol for the isolation of Campylobacter
spp and related organisms consisting of the combination
of one selective media and one filtration method was also
used.
Stool samples of patients younger than 2 years of age were
also evaluated for the presence of rotavirus and enteric
adenovirus since viral diarrhea is mainly observed in this
age group.
For molecular studies of D. fragilis, unpreserved stool
specimens from patients with a positive TFT set for Dien-
tamoeba fragilis were frozen at 20 8C. For DNA extraction
a high pure PCR template preparation kit (Roche) was used
with an additional preparation step for stool samples.
Aliquots of thawed stool samples (approximately 200 mg)
were dissolved in 1 ml of 5.6 M guanidine thiocyanate,
18 mM EDTA, 1% Triton X-100, 25 mM Tris-HCl (pH 6.4)
and vortexed for 1 min. Of the suspension, 200 ml was mixed
with 200 ml binding buffer and 40 ml of proteinase K atcomplete resolution of their symptoms. Only genotype 1 could be detected in D. fragilis infected
patients.
Conclusions: D. fragilis and G. lamblia were the most frequently encountered parasites in our
study population. Improved diagnostic tests are essential tools to study the prevalence and
pathogenesis of D. fragilis.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
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Table 1 Intestinal parasites isolated from 448 outpatients
suspected of suffering from a parasitic gastrointestinal dis-
ease, at the Saint-Pierre University Hospital in Brussels, from
January 2002 to December 2003
Pathogens Number
of patients
Prevalence
(%)
Potentially pathogenic protozoa
Giardia lamblia 32 7.1
Dientamoeba fragilis 28 6.3
Cryptosporidium parvum 7 1.6
Microsporidium spp 2 0.4
Isospora belli 1 0.2
Entamoeba histolytica 1 0.2
Non-pathogenic protozoa
Blastocystis hominis 44 9.8
Entamoeba coli 24 5.4
Iodamoeba bu¨tschlii 6 1.3
Endolimax nana 5 1.1
Chilomastix mesnili 2 0.4
Entamoeba hartmanni 1 0.2
Entamoeba dispar 1 0.2
Helminths
Trichuris trichiura 3 0.7
Ascaris lumbricoides 2 0.4
Strongyloides stercoralis 2 0.4
Taenia spp 2 0.4
Schistosoma mansoni 1 0.2
Enterobius vermicularis 1 0.2
Others helminths 2 0.420 mg/ml (both from Roche) and incubated at 70 8C for
10 min. After centrifugation for 1 min at 14 000  g the
supernatant was used for DNA extraction following the
instruction manual of the kit. At the end, the DNA was
eluted in 200 ml prewarmed (70 8C) elution buffer (Tris-HCl
10 mM, pH 8.5). For each series of isolation a mock DNA
isolation was performed containing no feces.
Primer DF1 (50CTC ATA ATC TAC TTG GAA CCA ATT30;
positions 100 to 123) and DF4 (50CCC CGA TTA TTC TCT TTG
ATA TT 30; positions 739 to 761) design was based on the
sequence of the ssu rRNA gene of D. fragilis (EMBL nucleo-
tide sequence database accession number U37461). Both
primers are complementary to the D. fragilis sequence but
have several mismatches at their 30 end compared to the
ssU rRNA genes from other trichomonads. For each series of
patient/control samples a negative control, containing no
DNA input was added. The PCR reaction mixture (50 ml)
contained 20 ml of DNA extract, 100 ng of each primer,
500 mM deoxynucleoside triphosphate mix, 5 ml of 10
magnesium free PCR buffer (Promega), 6 ml of 25 mM MgCl2
(Promega), 1 ml of bovine serum albumin (5 mg/ml)
(Roche), 1 ml of a-casein (20 mg/ml) to relieve PCR inhibi-
tion by fecal substances, and 0.2 ml (5 IU/ml) of Taq poly-
merase (in storage buffer B) (Promega). Forty cycles with
denaturation at 94 8C for 1 min, annealing at 52 8C for
1 min, and extension at 72 8C for 1 min were performed
with an additional extension step (72 8C) at the end for
10 min.
For RFLP 10 ml of the PCR reaction was digested with 10 U
of DdeI (Roche) in a final volume of 15 ml for 1 h at 37 8C.
Samples were loaded on a 9% polyacrylamide gel and run in
1 TBE (9 mM Tris/10 mM boric acid/1 mM EDTA, pH 8.3) at
100 V for 1.5 h. After electrophoresis, gels were stained with
ethidium bromide and photographed.
To assess the pattern of clinical disease, patients with D.
fragilis infection were compared to patients with G. lamblia
infection during the same study period. To achieve this, all
charts of patients with D. fragilis or G. lamblia infections
were reviewed retrospectively by combining the records of
the medical and microbiology departments.
A structured, close-ended questionnaire was used to
collect the patient’s history, age, sex and history of inter-
national travel. The clinical history included diarrhea
within the preceding three months, nature of the diarrhea,
abdominal pains, intensity of fever, nausea and/or vomit-
ing, urticaria, anal pruritus, anorexia, weight loss and
asymptomatic carriage (routine screening of enteric patho-
gens in stools of HIV-infected individuals, other immuno-
compromised states and patients from a foreign country
referred for surgery). Diarrhea was defined as at least three
unformed or liquid stools per day for at least three days.
Treatment history included antiparasitological drugs and
finally clinical status after one month of treatment (cure,
improvement or relapse).
Statistical analyses were performed with the Statistical
Package for Social Sciences 11.5 for Windows (SPSS Inc.,
Chicago, IL, USA) and EpiInfo v6.04c PLUS for DOS (Centers
for Disease Control and Prevention, Atlanta, GA, USA) soft-
ware. All parameters were compared between index patients
and controls. Comparisons were made by Fisher’s exact test
for small samples data. Odds ratios and 95% confidence
intervals were calculated.Results
TFTsets were filled with stool precisely according to instruc-
tions by 376/448 (83.9%) of the patients. Thirty seven per-
cent (139/376) had stools positive for potentially pathogenic
parasites after examination of the complete TFT test,
whereas intestinal parasites were observed in only six
(8.3%) of the 72 patients who only filled the second tube
without SAF fixative.
The relative frequency of D. fragilis compared to the
frequency of other enteric parasites over the same periods
is shown in Table 1.
D. fragilis and G. lamblia were detected in 28 (6.3%) and
32 (7.1%) of cases respectively. Other identified protozoan
pathogens included 7  Cryptosporidium parvum (1.6%) and
1  Entamoeba histolytica (0.2%). Non-pathogenic protozoa
such as Blastocystis hominis (9.8%), and Entamoeba coli
(5.4%) were also found.
Helminths such as Trichuris trichiura (0.7%), Strongyloides
stercoralis (0.4%), Taenia spp (0.4%), and Ascaris lumbri-
coides (0.4%) were also recovered but in small numbers.
Enterobius vermicularis and Schistosoma mansoni were each
observed in 0.2% of patients.
Microbiological and clinical features of patients with D.
fragilis and G. lamblia infections are shown in Table 2.
Microscopically inflammatory exudates, microscopic blood
in stool and concomitant infection with another enteric
parasite, virus or bacteria were encountered in both D.
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Table 2 Microbiological and clinical features of patients with Dientamoeba fragilis and Giardia lamblia infection
Patients with
D. fragilis infection
(n = 28) (%)
Patients with
G. lamblia infection
(n = 32) (%)
Odds ratio (95% CI) p Value
Median age (range) 26.1 (1—90 years) 24.2 (1—60 years)
Sex, male/female 1.15/1 2.2/1 0.52 (0.18—1.50) NS
Microbiological features
Leukocytes in stool 1/28 (3.6) 1/32 (3.1) 1.15 (0.07—19.25) NS
Red blood cells in stool 2/28 (7.1) 0/32 (0.0) — NS
Associated organisms 11/28 (39.3) 11/32 (34.4) 1.24 (0.43—3.54) NS
Clinical features
Diarrhea 16/26a (61.5) 23/29a (79.3) 0.42 (0.13—1.38) NS
Abdominal pain 18/26 (69.2) 21/29 (72.4) 0.86 (0.27—3.75) NS
Fever 1/26 (3.8) 0/29 (0.0) — NS
Weight loss 4/26 (15.4) 16/29 (55.2) 0.15 (0.04—0.54) 0.004
Nausea and/or vomiting 2/26 (7.7) 20/29 (69.0) 0.04 (0.01—0.19) 0.001
Urticaria 2/26 (7.7) 1/29 (3.4) 2.33 (0.20—27.36) NS
Anal pruritus 3/26 (11.5) 0/29 (0.0) — NS
Anorexia 3/26 (11.5) 17/29 (58.6) 0.09 (0.02—0.38) 0.001
Travel history 2/26 (7.7) 1/29 (3.4) 2.33 (0.20—27.36) NS
Treatment
Antiparasitic therapy 19/26 (73.1) 23/29 (79.3) 0.71 (0.20—2.47) NS
Relapse 4/19 (21.1) 2/23 (8.7) 2.80 (0.45—17.32) NS
NS, p > 0.05.
a Two patients with D. fragilis and G. lamblia co-infection were excluded in the comparison of the clinical features and treatment, and the
clinical file of one patient with G. lamblia infection was unavailable.fragilis and G. lamblia infections. Eleven patients with D.
fragilis had a co-infection: Campylobacter jejuni (1), Sal-
monella enterica (1), and G. lamblia (2). In seven patients
non-pathogenic protozoa were observed: Blastocystis homi-
nis (2), Entamoeba coli (2), Endolimax nana (2), and Ioda-
moeba bu¨tschlii (1).
In 11 patients with G. lamblia infection, co-infection with
other parasites, viruses or bacteria was observed: Salmonella
enterica (2), Campylobacter jejuni (1), D. fragilis (2), and
rotavirus (1). In five cases co-infection was observed with
non-pathogenic enteric protozoa: Blastocystis hominis (3),
Entamoeba coli (1), and Iodamoeba bu¨tschlii (1).
Because medical records were unavailable for one patient
with G. lamblia infection and because two patients were
co-infected with D. fragilis and G. lamblia, 26 cases of D.
fragilis were compared against 29 cases of G. lamblia for the
clinical features of the infection. The median age of cases
with D. fragilis was 26.1 years (95% CI: 18.6—35.3) and with
G. lamblia 24.2 years (95% CI: 16.1—29.7). Sex distribution as
well as history of international travel was similar for patients
colonized by either species.
The most frequent symptoms associated with D. fragilis
infection were abdominal pain (69.2%) and diarrhea (61.5%)
(Table 2). Less frequently observed were weight loss
(15.4%), anorexia (11.5%), and anal pruritus (11.5%). Only
four out of 26 were asymptomatic. The most important
symptomatology in cases with G. lamblia infection were
diarrhea (79.3%), abdominal pain (72.4%), nausea and/or
vomiting (69.0%), anorexia (58.6%), and weight loss (55.2%).
Diarrhea, abdominal pain, fever, and urticaria were
observed as frequently in cases with D. fragilis as in G.lamblia infection. Symptoms such as weight loss, nausea
and/or vomiting, and anorexia differed significantly
between the two infections (Table 2).
A similar percentage of patients with D. fragilis (73.1%)
was treated with antiparasitological drugs as for G. lamblia
(79.3%) ( p > 0.05). From 26 cases with D. fragilis, 19 (73.1%)
were treated, 15 (78.9%) with metronidazole and four
(21.1%) with paromomycin. In cases treated with metroni-
dazole and paromomycin, 12/15 and 4/4, respectively, had a
follow-up TFTone month later to check parasitological effec-
tiveness. Treatment with metronidazole was parasitologi-
cally effective in 8/12 (66.7%) and paromomycin in 4/4
(100%). All patients presenting a parasitological cure also
reported a clinical cure, whereas among the four patients
with persistent D. fragilis infection three of them improved
their health status and in one there was no difference in
symptomatology after treatment.
From the 29 cases with G. lamblia, 23 (79.3%) received
treatment, 20 (87.0%) with nitroimidazole drugs such as
metronidazole or tinidazole, whereas two (8.7%) and one
(4.3%) were treated with albendazole and paromomycin,
respectively. Among these, 16/23 had a follow-up TFT one
month later to check parasitological cure, 15 patients trea-
ted with nitroimidazole drugs and one patient treated with
paromomycin. Treatment with nitroimidazole was parasito-
logically effective in 13/15 (86.7%) cases and paromomycin
in the one (100.0%) case. All patients with a treated G.
lamblia infection, with negative TFT follow-up, were clini-
cally cured whereas in the two patients with persistent
G. lamblia infection there was no difference in symptoma-
tology after treatment.
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Figure 1 Restriction endonuclease digestion with DF1/DF4
PCR products from nine patient samples (lanes 1—9) and of
PCR products of D. fragilis genotype 1 (lane 11) and genotype
2 (lane 10) with DdeI. The marker (lane M) is a 100 bp ladder.From the 15 samples conserved in good storage conditions
for PCR testing, nine samples were positive for D. fragilis (six
from patients with abdominal complaints and three from
asymptomatic carriers). Digestion with DdeI revealed that
all nine samples presented a restriction fragment pattern
identical to the genotype 1 of D. fragilis (Figure 1).
Discussion
Since its first description by Jepps and Dobell in 1918,
Dientamoeba fragilis continues to be a neglected cause
of gastrointestinal symptomatology in many countries. In
our study, D. fragilis was the second most frequent patho-
genic intestinal protozoan detected with a prevalence of
6.3% in patients suspected of having a parasitic infection of
the gastrointestinal tract. In other industrialized countries,
estimated prevalence of infection among the general popu-
lation ranges from 1.5% to 42%, according to the diagnostic
methods used.3 Much higher rates are seen in institutions or
crowded settings where hygiene is inadequate. In a semi-
communal group of adults in the USA an infection rate as
high as 53% has been reported.12 D. fragilis is also common
in developing countries,13,14 and accounts for 2.25% of
enteric parasites isolated from children with diarrhea in
Honduras.15 In Oman, Windsor observed D. fragilis to be the
second most common pathogenic organism observed (5.1%)
in stool specimens after the non-pathogenic protozoan
Blastocystis hominis (15.6%).16
Variations in parasitological routine diagnosis procedures
used in different laboratories may account for disparity in
results. In most European countries, parasitological routine
diagnosis is usually performed with the examination of only
one unpreserved stool specimen. Because vegetative stages
of protozoa are fragile and intestinal parasites are intermit-
tently shed, the yield of this examination is low.17,18 To
improve the yield in routine diagnosis of intestinal parasites,
the triple feces test (TFT) was developed; this combines the
collection of three samples on three consecutive days, the
use of sodium acetate acetic acid formalin (SAF) preservative
and permanent staining with chlorazol black.10 The introduc-
tion of this protocol in our laboratory allowed us to increase
the recovery of intestinal parasites up to 37% as compared to
11%with the procedure using only one fresh stool specimen.19Similar results were obtained by van Gool et al., who
showed that TFT in a routine clinical setting strongly
improved diagnosis of intestinal parasites when compared
to the conventional method of examination of one unpre-
served stool specimen after ether-sedimentation. In this
study, the conventional method and TFTallowed the recovery
of one or more parasitic species in the stools in 106/462
(22.9%) and 209/462 (45.2%) cases, respectively.10
From earlier studies it is known that a proportion of
patients infected with D. fragilis remain asymptomatic.5,20
This was also true for 15.4% of patients in our study
population. Several studies have also shown that a large
proportion of G. lamblia infected patients will not develop
any enteric symptoms or that cysts of G. lamblia may be
shed in the stool of infected patients for weeks to months
after symptoms disappear.21,22 One hypothesis to explain
this phenomenon could be that D. fragilis constitutes a
heterogenic species with similar morphology but with
genetic diversity. We therefore tested several isolates with
a recently developed PCR/RFLP for D. fragilis.9 As observed
in the former study, all nine D. fragilis isolates tested
belonged to genotype 1. Similar results were also found
by Windsor et al. who were unable to find genotype 2 in a
series of 43 culture isolates of this protozoon.23 The failure
to obtain PCR products in six of 15 unpreserved stool
specimens tested is probably due to inadequate storage
conditions and/or an excessive delay before starting the
extraction procedure as recently described by Stark et al.24
Although the number of isolates is small and differences
in genotypic variation can go unnoticed, our findings sug-
gest that this may not be the predominating factor for
pathogenicity.
Several reports from many parts of the world describe an
association betweenD. fragilis and clinical symptomatology,
principally abdominal pain, diarrhea, nausea, vomiting and
flatus.3—7,25 In our study, complaints of diarrhea and abdom-
inal pain also predominated. Clinical symptomatology of G.
lamblia and D. fragilis infection did show many similarities.
However, patients with D. fragilis infections suffered sig-
nificantly less frequently from nausea and/or vomiting,
anorexia and weight loss. Anal pruritus was not more com-
mon in patients with D. fragilis than in those with G. lamblia
infection. Links between D. fragilis and anal pruritus have
been described by Spencer et al.4 Several authors have
suggested that D. fragilis could be transmitted by the eggs
of Enterobius vermicularis. Burrows and Swerdlow were the
first to publish a study that showed a greater than expected
incidence of co-infections of D. fragilis with E. vermicu-
laris.26 We were unable to confirm this finding in our study
population. Also, contrary to Yang and Scholten, we could
not find an association between D. fragilis infection and
urticaria.2
Use of antiparasitic drugs in patients with D. fragilis
infection led to an improvement of symptoms in 78.9%,
and in 75.0% a disappearance of parasites from stool. Par-
omomycin proved to be the most effective drug with para-
sitological cure in all four cases. This was also reported by
Simon et al. who cured all 21 cases of D. fragilis infection
using 25—35 mg/day for 4—5 days.27 Apart from the direct
action of the drug, disappearance of symptoms could also be
due to a self-limiting character of the infection, as can be
observed in cases with G. lamblia infection.28 Indeed, among
260 O. Vandenberg et al.the seven patients with D. fragilis infection who were not
treated, only two had persistent symptoms. In a recent study,
Bosman et al. reported strong clinical improvement in 27/33
(82%) of children effectively treated with clioquinol for D.
fragilis infection.29 Treatment with clioquinol was parasito-
logically effective in 81% and nitro-imidazoles, metronida-
zole or tinidazole in 69% of cases.29 In our study, the clinical
effect of 10 days metronidazole treatment was moderate
(66.7%). Similar results have been reported by Preiss et al.
who observed a 70% success rate.30
Long-term treatment with high doses of clioquinol has
been associated with neurological and ocular side-effects.31
In our hospital this drug is therefore not recommended for
clinical use. Instead, paromomycin and nitroimidazoles can
be used for the treatment of D. fragilis. In vitro studies have
also demonstrated effectiveness of paromomycin and metro-
nidazole upon D. fragilis.32 Because these studies were
performed with dixenic cultures in which bacteria are neces-
sary for growth of the parasite, results may have been biased
by the simultaneous effect upon bacterial growth. Develop-
ment of susceptibility testing on axenic cultures is therefore
much needed.
In conclusion, in our study population, D. fragilis was
found to be the second most common pathogenic protozoan
isolated. Symptomatology of patients infected with D. fra-
gilis did showmany similarities withG. lamblia infection, and
most patients receiving treatment showed good parasitolo-
gical responses and health improvement.
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